New drug combo shows promise for tough liver cancer
NCT ID NCT04180072
First seen Apr 30, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tests a combination of two drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink or control the cancer. Participants receive the drugs by IV and are monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital
Linkou District, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Mackay Memorial Hospital
Taipei, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.